['gout']
['rdea3170 2.5 mg', 'allopurinol 300 mg']

        Inclusion Criteria:

          -  Subject is able to understand the study procedures and the risks involved and is
             willing to provide written informed consent before the first study-related activity.

          -  Subject meets one or more criteria for the diagnosis of gout as per the American
             Rheumatism Association Criteria for the Classification of Acute Arthritis of Primary
             Gout.

          -  Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 45
             kg/m2.

          -  Subject has a Screening serum urate level ≥ 8 mg/dL.

          -  Subject is free of any clinically significant disease or medical condition, per the
             Investigator's judgment.

        Exclusion Criteria:

          -  Subject is unable to take colchicine for gout flare prophylaxis.

          -  Subject has a history or suspicion of kidney stones.

          -  Subject has any gastrointestinal disorder that affects motility and/or absorption.

          -  Subject had unstable angina, New York Heart Association class III or IV heart failure,
             ischemic heart disease, stroke, or deep venous thrombosis within 12 months prior to
             Day 1; or subject is currently receiving anticoagulants.

          -  Subject has Screening laboratory parameters that are outside the normal limits and are
             considered clinically significant by the Investigator.

          -  Subject has an estimated creatinine clearance < 60 mL/min calculated by the
             Cockcroft-Gault formula using ideal body weight during the Screening period.

          -  Subject is taking losartan, fenofibrate, guaifenesin, or sodium-glucose linked
             transporter-2 inhibitors; chronic and stable doses are permitted if doses are stable
             for at least 14 days prior to study medication dosing.

          -  Subject is unable or unwilling to comply with the study requirements or has a
             situation or condition that, in the opinion of the Investigator, may interfere with
             participation in the study.
      